DNX and XL-protein Announce Collaboration to Develop Novel, Long-Acting Biopharmaceutical Products
New Half-Life Extension Platform Technology Will Support the…
XL-protein Signs Licensing Agreement with MSD Animal Health to Develop Biopharmaceuticals using its PASylation® Technology
FREISING, GERMANY, February 12, 2015 – XL-protein GmbH, Germany,…
XL-protein and YEDA sign business collaboration agreement to commercialize PASylated interferon superagonist
FREISING, GERMANY & REHOVOT, ISRAEL, October 21, 2014 –
Yeda…